Media coverage about Windtree Therapeutics (NASDAQ:WINT) has been trending somewhat positive this week, according to Accern. Accern rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Windtree Therapeutics earned a coverage optimism score of 0.16 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 44.7668886090551 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Windtree Therapeutics (NASDAQ:WINT) traded up $0.51 during mid-day trading on Tuesday, reaching $0.81. Windtree Therapeutics has a one year low of $0.18 and a one year high of $2.00. The company has a current ratio of 0.97, a quick ratio of 0.97 and a debt-to-equity ratio of -1.09.

Windtree Therapeutics (NASDAQ:WINT) last released its earnings results on Monday, August 21st. The biotechnology company reported ($0.76) EPS for the quarter, beating the consensus estimate of ($0.99) by $0.23. The business had revenue of $1.15 million for the quarter, compared to analyst estimates of $0.40 million.

Separately, Zacks Investment Research raised shares of Windtree Therapeutics from a “hold” rating to a “buy” rating and set a $0.25 target price for the company in a research note on Wednesday, August 30th.

TRADEMARK VIOLATION WARNING: This article was first posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The original version of this article can be viewed at https://www.watchlistnews.com/windtree-therapeutics-wint-given-news-sentiment-rating-of-0-16/1686502.html.

Windtree Therapeutics Company Profile

Windtree Therapeutics, Inc, formerly Discovery Laboratories, Inc, is a biotechnology company. The Company is focused on developing KL4 surfactant therapies for respiratory diseases and other potential applications. The Company operates through the research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products segment.

Insider Buying and Selling by Quarter for Windtree Therapeutics (NASDAQ:WINT)

Receive News & Ratings for Windtree Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Windtree Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.